Mr. Speaker, we heard from the chief negotiators on CETA that the phase-in would take place over the course of 10 years.
Looking at the cost of pharmaceutical drugs, if there is no clear measurement on that, then we as Canadians should always be concerned about that.
Looking at past trade agreements, would my hon. colleague not agree with me that we should not be making rash decisions, that we should be working with all stakeholders to keep the cost of prescription drugs down and not scare Canadians about something that may not take effect?